New Blood Test Boosts Early Liver Cancer Detection

Helio Genomics and LiverRight have forged a strategic alliance to enhance early liver cancer detection across the United States. This collaboration leverages Helio's advanced LiverTrace blood test, which utilizes artificial intelligence and machine learning to identify cancer biomarkers.

The LiverTrace technology is capable of detecting early signs of liver cancer, even before tumors become apparent through traditional imaging methods like ultrasound. Patients receiving concerning results are seamlessly connected to LiverRight's network of hepatology professionals for immediate consultation and care.

This partnership signifies a shared commitment to improving survival rates for liver cancer. By facilitating prompt diagnosis and specialist intervention, the initiative aims to make potentially curative treatments, such as liver transplantation, more accessible to at-risk individuals.